| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/08/2011 | CA2361251C Formulations comprising antisense nucleotides to connexins |
| 03/08/2011 | CA2343840C Use of a cytokine-producing lactococcus strain to treat colitis |
| 03/08/2011 | CA2329054C A novel polypeptide hormone phosphatonin |
| 03/08/2011 | CA2240516C Novel tyrosine kinase receptors and ligands |
| 03/08/2011 | CA2137377C Retinal pigmented epithelium derived neurotrophic factor |
| 03/03/2011 | WO2011026132A2 Methods and compositions for the inhibition of transplant rejection |
| 03/03/2011 | WO2011026122A2 B7-h4 fusion proteins and methods of use thereof |
| 03/03/2011 | WO2011026112A1 Compositions comprising specific ugt inhibitors and methods of use thereof |
| 03/03/2011 | WO2011026111A1 Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
| 03/03/2011 | WO2011026041A2 Sdf-1 delivery for treating ischemic tissue |
| 03/03/2011 | WO2011026015A2 Stabilized melanocortin ligands |
| 03/03/2011 | WO2011025996A2 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency |
| 03/03/2011 | WO2011025875A1 Echinocandin derivatives |
| 03/03/2011 | WO2011025849A1 Processes for preparing protease inhibitors of hepatitis c virus |
| 03/03/2011 | WO2011025792A1 Compositions for absorption and sustained action of leptin-related peptides |
| 03/03/2011 | WO2011025755A1 Synthesis of oxygen carrying, turbulence resistant, high density submicron particulates |
| 03/03/2011 | WO2011025734A1 Methods and compositions for preventing or treating ophthalmic conditions |
| 03/03/2011 | WO2011025635A2 Cosmetic uses of modified stressed yeast extracts and related compositions |
| 03/03/2011 | WO2011025524A1 Methods for treating conditions mediated by the inflammatory cytokine cascade using gapdh inhibitors |
| 03/03/2011 | WO2011025107A1 Composition for relieving pruritus |
| 03/03/2011 | WO2011025050A1 Apoptosis inducer |
| 03/03/2011 | WO2011025036A1 Particle composition and medicinal composition comprising same |
| 03/03/2011 | WO2011024973A1 Therapeutic agent for rhinitis |
| 03/03/2011 | WO2011024763A1 Prophylaxis, therapeutic agent, or anorexiant for diabetes |
| 03/03/2011 | WO2011024480A1 Drug composition for angiogenesis therapy |
| 03/03/2011 | WO2011024433A1 Lung and esophageal cancer related gene adamts18 |
| 03/03/2011 | WO2011024146A2 Adam12 inhibitors and their use against inflammation-induced fibrosis |
| 03/03/2011 | WO2011024110A2 Glucagon-like peptide-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| 03/03/2011 | WO2011024079A2 New peptoid agonists of nerve growth factor receptor and their use as medicaments |
| 03/03/2011 | WO2011024025A1 An erythropoietin analogue and a method thereof |
| 03/03/2011 | WO2011023805A1 Use of plasmin for the treatment of filtration failure after trabeculectomy |
| 03/03/2011 | WO2011023785A1 Targeting tissue factor to activated platelets |
| 03/03/2011 | WO2011023702A1 New endolysin obpgplys |
| 03/03/2011 | WO2011023250A1 Treatment of neurological or neurodegenerative disorders |
| 03/03/2011 | WO2011023249A1 Treatment of neurological of neurodegenerative disorder |
| 03/03/2011 | WO2011023213A1 Modified chemodenervating agents |
| 03/03/2011 | WO2011022850A2 Uninterruptible power supply for a medical administration appliance |
| 03/03/2011 | WO2011022843A1 Use of a holotoxin to reduce endoplasmic reticulum-associated degradation of misfolded proteins |
| 03/03/2011 | WO2011022753A1 Composition and method for the treatment or prevention of spinal disorders iii |
| 03/03/2011 | WO2011017502A9 Formulations comprising linaclotide |
| 03/03/2011 | WO2011005525A3 Prodrug anti-cancer therapy |
| 03/03/2011 | WO2011005406A3 Skin repair compositions comprising circadian gene activators and a synergistic combination of sirt1 gene activators |
| 03/03/2011 | WO2010141143A3 Engineered avirulent bacteria strains and use in medical treatments |
| 03/03/2011 | WO2010136548A3 Fibrosuppressant biotherapeutics |
| 03/03/2011 | WO2010132622A3 Anticd20-cpg conjugates and methods of treating b cell malignancies |
| 03/03/2011 | WO2010132561A8 New human rotavirus strains and vaccines |
| 03/03/2011 | WO2010121023A3 Peptides and aptamers for targeting of neuron or nerves |
| 03/03/2011 | WO2010120691A3 Methionine sulfoxide peptide, compositions and methods of use |
| 03/03/2011 | WO2010117957A3 Methods and materials for delivering molecules |
| 03/03/2011 | WO2010117727A3 Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions |
| 03/03/2011 | WO2010111421A3 Isoform nell-1 peptide |
| 03/03/2011 | WO2010111240A3 Methods for treating inflammatory arthritis |
| 03/03/2011 | WO2010108154A3 Selective and potent peptide inhibitors of kv1.3 |
| 03/03/2011 | WO2010107825A3 Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities |
| 03/03/2011 | WO2010104341A9 Compositions for diagnosis of fungal infections |
| 03/03/2011 | WO2010102266A8 Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects |
| 03/03/2011 | WO2010101793A3 Methods and compositions for the diagnosis, prognosis and treatment of cancer |
| 03/03/2011 | WO2010029545A3 Compositions and methods for treating s. pneumoniae infection |
| 03/03/2011 | WO2010011767A8 Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis |
| 03/03/2011 | WO2009002931A3 Methods and uses thereof of prosaposin |
| 03/03/2011 | US20110055942 Single domain TDF-related compounds and analogs thereof |
| 03/03/2011 | US20110055940 Therapeutic Inhibitors of PAI-1 Function Methods of Their Use |
| 03/03/2011 | US20110054442 Cell Membrane Translocation of Regulated Snare Inhibitors, Compositions Therefor, and Methods for Treatment of Disease |
| 03/03/2011 | US20110054410 Liquid formulation of fsh |
| 03/03/2011 | US20110054347 Devices for Selective Recruitment, Isolation, Activation, and/or Elimination of Various Cell Populations |
| 03/03/2011 | US20110054159 Rna interference mediating small rna molecules |
| 03/03/2011 | US20110054153 Method of purifying apo-2 ligand/trail usin crystallisation the cold |
| 03/03/2011 | US20110054152 Hydroxyalkyl Starch Derivatives |
| 03/03/2011 | US20110054003 Antisense oligonucleotide modulation of stat3 expression |
| 03/03/2011 | US20110053866 Pharmaceutical compositions |
| 03/03/2011 | US20110053865 Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| 03/03/2011 | US20110053864 Compositions and methods for modulation of cell migration |
| 03/03/2011 | US20110053863 Methods of using flt3-ligand in the treatment of cancer |
| 03/03/2011 | US20110053862 Compositions comprising survivin sirna and methods of use thereof |
| 03/03/2011 | US20110053861 Compositions comprising nuclear factor-kappa b (nf-kb) sirna and methods of use |
| 03/03/2011 | US20110053860 COX-2 function and wound healing |
| 03/03/2011 | US20110053859 Methods to reduce the effects of sleep deprivation |
| 03/03/2011 | US20110053858 Heterocyclic peptide ketoamides |
| 03/03/2011 | US20110053857 Yeast cells expressing tar dna-binding protein 43 and uses therefor |
| 03/03/2011 | US20110053856 Metabolite derivatives of the hdac inhibitor fk228 |
| 03/03/2011 | US20110053855 Ex vivo cell stimulation |
| 03/03/2011 | US20110053854 Treatment of muscular dystrophies and related disorders |
| 03/03/2011 | US20110053853 Use of copolymer 1 for treatment of muscular dystrophy |
| 03/03/2011 | US20110053852 Use of podocan protein in treating cardiovascular diseases |
| 03/03/2011 | US20110053851 Haemostasis-modulating compositions and uses therefor |
| 03/03/2011 | US20110053850 Doc1 compositions and methods for treating cancer |
| 03/03/2011 | US20110053849 Regulation of litaf modulated cytokine production by a novel p53 short peptide |
| 03/03/2011 | US20110053848 Prodrug comprising a drug linker conjugate |
| 03/03/2011 | US20110053847 Methods of treating vasodilatory shock |
| 03/03/2011 | US20110053846 The use of gnrh antagonist peptide in the treatement of sex hormone-dependent diseases |
| 03/03/2011 | US20110053845 Localized vaginal delivery without detrimental blood levels |
| 03/03/2011 | US20110053844 Liquid formulation of g-csf conjugate |
| 03/03/2011 | US20110053843 E-selectin compositions and use thereof for inducing e-selectin tolerance |
| 03/03/2011 | US20110053842 Targeted therapeutics based on engineered proteins that bind egfr |
| 03/03/2011 | US20110053841 N-terminal fgf variants having increased receptor selectivity and uses thereof |
| 03/03/2011 | US20110053840 Allele and isotope-specific intervention on mhc class ii molecules associated with autoimmune diseases by means of peptides |
| 03/03/2011 | US20110053839 GLP-1 Derivatives II |
| 03/03/2011 | US20110053838 Process for solubilizing glucagon-like peptide 1 compounds |
| 03/03/2011 | US20110053837 Mineral-peptide chelates |
| 03/03/2011 | US20110053836 Use of defensins against tuberculosis |